Octreotide Market Report 2026

The octreotide market size has grown steadily in recent years. It will grow from $2.56 billion in 2025 to $2.69 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to clinical success in acromegaly treatment, rising diagnosis of neuroendocrine tumors, availability of depot formulations, expansion of endocrine specialty care, hospital-based hormone therapy adoption.

The octreotide market size is expected to see steady growth in the next few years. It will grow to $3.26 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growth in long-acting injectable demand, increasing prevalence of endocrine disorders, expansion of oncology indications, rising hospital infusion capacity, innovation in sustained-release formulations. Major trends in the forecast period include increasing use in hormonal disorder management, growing adoption of long-acting injectable formulations, expansion in neuroendocrine tumor treatment, rising demand for hospital-administered therapies, increased focus on symptom control in chronic conditions.

The rising incidence of cancer is anticipated to fuel the expansion of the octreotide market in the future. Cancer comprises diseases marked by the uncontrolled proliferation and dissemination of abnormal cells throughout the body. The surge in cancer cases stems primarily from aging demographics, environmental influences, lifestyle factors, and advances in diagnostic techniques. Octreotide addresses escalating cancer rates by suppressing tumor development, managing hormone-dependent cancers, and easing related symptoms. For instance, in May 2024, reports from the National Cancer Institute (NCI), a U.S. government agency, indicated nearly 20 million new cancer cases and 9.7 million deaths globally, with forecasts for 2040 reaching 29.9 million cases and 15.3 million deaths. Thus, the growing prevalence of cancer is propelling the octreotide market forward.

Major companies in the octreotide market are prioritizing the development of innovative products, like injectable suspensions, to enhance patient compliance and ease of use. These injectable suspensions act quickly when delivered via injection, enabling rapid absorption into the bloodstream and skipping the digestive tract for a faster therapeutic effect. For example, in October 2024, Teva Pharmaceuticals, a company based in Israel, introduced a generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension), formulated for injection to achieve swift bloodstream absorption. Octreotide serves as a synthetic version of the hormone somatostatin and is mainly prescribed for treating acromegaly, carcinoid syndrome, and VIP-secreting tumors. This injectable approach provides a speedier onset than conventional oral tablets, helping patients stick better to their regimens.

In April 2023, Italy-based pharmaceutical company Chiesi Farmaceutici S.p.A. acquired Amryt Pharma Plc for an undisclosed sum. This strategic move enables Chiesi to expand its rare disease portfolio, bolstering its ability to deliver innovative therapies. The acquisition also advances Chiesi's initiatives to enhance patient access to transformative treatments for rare and complex disorders. Amryt Pharma Plc, an Ireland-based biopharmaceutical firm, focuses on developing and commercializing octreotide-based therapies for rare and orphan diseases.

Major companies operating in the octreotide market are Novartis International AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Bachem Holding AG, Chemi S.p.A., LGM Pharma LLC, Hainan Shuangcheng Pharmaceuticals Co. Ltd., USV Private Limited, ChemWerth Inc., Shanghai Soho-Yiming Pharmaceuticals Co. Ltd., Neiss Labs Private Limited, Samarth Life Sciences Private Limited, TAPI Technology & API Services, BCN Peptides S.A.

North America was the largest region in the octreotide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the octreotide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the octreotide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the octreotide market by increasing the cost of injectable drug components, sterile processing materials, and cold chain logistics required for peptide based therapies. These effects are most significant in hospital pharmacy distribution and specialty endocrine clinics, where handling requirements and supply continuity are critical. Regions such as Europe and North America have experienced higher input costs due to reliance on global injectable drug supply chains. Rising tariff related expenses have influenced procurement planning, pricing strategies, and inventory management. However, tariffs have also driven investment in localized injectable manufacturing, improved supply chain optimization, and greater long term resilience.

The octreotide market research report is one of a series of new reports that provides octreotide market statistics, including octreotide industry global market size, regional shares, competitors with a octreotide market share, detailed octreotide market segments, market trends and opportunities, and any further data you may need to thrive in the octreotide industry. This octreotide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Octreotide, a synthetic version of somatostatin, treats various medical conditions by suppressing hormone secretion. It comes in short-acting and long-acting forms to help control hormone-related disorders, though it can lead to side effects like gastrointestinal problems and gallstones.

The primary forms of octreotide include octreotide acetate, octreotide, octreotide chloride, octreotide hydrochloride, and indium in-111 octreotide. Octreotide acetate serves as a synthetic version of somatostatin, applied in treating hormone-producing tumors, acromegaly, and intense diarrhea linked to specific cancers. These forms come in options like injections, powders, and microspheres, prescribed for issues including diarrhea, acromegaly, and similar conditions. Distribution occurs through hospital pharmacies, online pharmacies, and retail pharmacies, mainly serving end-users in pharmaceutical and clinical research areas.

The octreotide market consists of sales of short-acting octreotide formulations, long-acting octreotide formulations, and other extended-release formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.